Melanoma in 2017: Moving treatments earlier to move further forwards

Melanoma in 2017: Moving treatments earlier to move further forwardsMelanoma in 2017: Moving treatments earlier to move further forwards, Published online: 28 November 2017; doi:10.1038/nrclinonc.2017.183In 2017, results from phase III trials demonstrated the impressive safety and efficacy of adjuvant targeted and immune therapies in patients with resectable stage III–IV melanoma, and raised questions about the surgical management of patients with microscopic sentinel-lymph-node metastases. For patients with unresectable disease, new overall survival data added to the debate about the relative benefits of single-agent anti-PD-1 versus combined anti-PD-1 and anti-CTLA-4 immunotherapy.
Source: Nature Clinical Practice Oncology - Category: Cancer & Oncology Authors: Source Type: research